The NRF2/Keap1 pathway as a therapeutic target in inflammatory bowel disease.
Geertsema S, Bourgonje AR, Fagundes RR, Gacesa R, Weersma RK, van Goor H, Mann GE, Dijkstra G, Faber KN.
Geertsema S, et al. Among authors: fagundes rr.
Trends Mol Med. 2023 Oct;29(10):830-842. doi: 10.1016/j.molmed.2023.07.008. Epub 2023 Aug 7.
Trends Mol Med. 2023.
PMID: 37558549
Review.